ICD-10 Coding for Hepatocellular Carcinoma(C22.0, C22.9)
Complete ICD-10-CM coding and documentation guide for Hepatocellular Carcinoma. Includes clinical validation requirements, documentation requirements, and coding pitfalls.
Also known as:
Related ICD-10 Code Ranges
Complete code families applicable to Hepatocellular Carcinoma
C22.0-C22.9Primary Range
Malignant neoplasms of liver and intrahepatic bile ducts
This range includes codes for primary liver cancers, including hepatocellular carcinoma.
Code Comparison: When to Use Each Code
Compare key differences between these codes to ensure accurate selection
| Code | Description | When to Use | Key Documentation |
|---|---|---|---|
| C22.0 | Liver cell carcinoma | Use when imaging or biopsy confirms hepatocellular carcinoma. |
|
| C22.9 | Malignant neoplasm of liver, unspecified | Use when liver malignancy is suspected but not yet confirmed as HCC. |
|
Clinical Decision Support
Always review the patient's clinical documentation thoroughly. When in doubt, choose the more specific code and ensure documentation supports it.
Key Information: ICD-10 code for hepatocellular carcinoma
Essential facts and insights about Hepatocellular Carcinoma
Primary ICD-10-CM Codes for hepatocellular carcinoma
Decision Criteria
clinical Criteria
- Confirmed hepatocellular carcinoma via imaging or biopsy
Applicable To
- Hepatocellular carcinoma
Excludes
- Cholangiocarcinoma (C22.1)
Clinical Validation Requirements
- Imaging showing arterial hypervascularity and portal/delayed phase washout
- Biopsy confirming hepatocellular origin
Code-Specific Risks
- Incorrectly coding without proper imaging or biopsy confirmation
Coding Notes
- Ensure imaging or biopsy confirms diagnosis before coding.
C22.9 - Malignant neoplasm of liver, unspecified
Use when liver malignancy is suspected but not yet confirmed as HCC.
Excludes
- Liver cell carcinoma (C22.0)
Clinical Validation Requirements
- Use when imaging suggests malignancy but histology is pending
Coding Notes
Use as a temporary code until specific diagnosis is confirmed.
Ancillary Codes
Additional codes that should be used in conjunction with the main diagnosis codes when applicable.
Chronic viral hepatitis C
B18.2Documentation & Coding Risks
Avoid these common documentation and coding issues when documenting Hepatocellular Carcinoma to ensure proper reimbursement, maintain compliance, and reduce audit risk. These guidelines are particularly important when using ICD-10 code C22.0.
Impact
Clinical: Misrepresentation of patient condition., Regulatory: Non-compliance with coding standards., Financial: Potential for claim denials.
Mitigation Strategy
Confirm diagnosis with imaging or biopsy before coding., Review documentation for specificity.
Impact
Reimbursement: Incorrect sequencing can lead to denied claims., Compliance: Non-compliance with ICD-10 coding guidelines., Data Quality: Inaccurate clinical data representation.
Mitigation Strategy
Follow CMS etiology/manifestation rules to sequence underlying conditions first.
Impact
Incorrect sequencing of HCC and underlying conditions.
Mitigation Strategy
Educate coding staff on proper sequencing rules.
Documentation errors, coding pitfalls, and audit risks are interconnected aspects of medical coding and billing. Addressing all three areas helps ensure accurate coding, optimal reimbursement, and regulatory compliance.
Frequently Asked Questions
Common questions about ICD-10 coding for Hepatocellular Carcinoma, with expert answers to help guide accurate code selection and documentation.
Documentation Templates for Hepatocellular Carcinoma
Use these documentation templates to ensure complete and accurate documentation for Hepatocellular Carcinoma. These templates include all required elements for proper coding and billing.
Oncology Progress Note
Specialty: OncologyRequired Elements
- Tumor characteristics
- Liver function
- Treatment plan
Example Documentation
Examples: Poor vs. Good Documentation
Poor Documentation Example
Good Documentation Example
Explanation
Need help with ICD-10 coding for Hepatocellular Carcinoma? Ask your questions below.